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We examined the transmission of human papillomavirus 
(HPV) in 25 heterosexual, monogamous couples (25 men, 
25 women), followed up over an average of 7.5 months. A 
total of 53 heterosexual transmission events were observed 
among 16 couples (14 male-to-female and 39 female-to-
male). Sexual transmission involved 13 different oncogenic 
and nononcogenic HPV types; 8% were vaccine-covered 
types transmitted between partners. The overall rate of HPV 
transmission from the penis to the cervix was 4.9/100 per-
son-months, which was substantially lower than that from 
the cervix to the penis (17.4/100 person-months). Trans-
mission between the hands and genitals, as well as ap-
parent self-inoculation events (primarily in men), were also 
observed. Couples who transmitted HPV were more sexu-
ally active and used condoms less frequently. These results 
have implications for HPV prevention and control strategies, 
including the targeting of prophylactic vaccines.  
C
ervical cancer remains a major source of illness and 
death among women globally, and infection with on-
cogenic human papillomaviruses (HPVs) is its principal 
cause (1,2). Men are assumed to be the main reservoirs of 
genital HPV infection for women, although comparatively 
little is known about the natural history of HPV in men. 
A limited number of cross-sectional and case-control 
studies have evaluated genotype-speciﬁ   c HPV concor-
dance in male-female couples (3–7). There are, however, 
no empirical data on the heterosexual transmission of HPV. 
Our investigation evaluates the transmission of HPV in a 
cohort of male-female sexual partners. 
Methods 
Study Participants
The study was conducted at the University Health Ser-
vices of the University of Hawaii at Manoa from February 
2005 through November 2006. Promotional efforts includ-
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ed ﬂ  yers and email invitations, which were part of larger 
ongoing studies of HPV. The study was approved by the 
Committee on Human Studies of the University of Hawaii. 
All study participants provided written informed consent. 
Eligible participants were at least 18 years of age, English-
speaking, not currently pregnant, and in a monogamous re-
lationship with the index partner.
Specimen Collection
Couples attended concurrent study visits at 2-month 
intervals. Trained clinicians collected exfoliated cell sam-
ples for HPV DNA detection. For men, separate genital 
specimens from the penis glans/corona, penis shaft, scro-
tum, and inner foreskin (uncircumcised men) were col-
lected by using textured paper and a saline-moistened 
swab (8,9). Anal canal specimens were collected by using 
a saline-moistened swab. A cytobrush was used to collect 
oral specimens (buccal cavity, tongue). Specimens from 
the dominant hand (palm, ﬁ  ngertips, under the ﬁ  nger-
nails) were collected by using a saline-moistened swab. 
Participants self-collected ﬁ  rst-catch urine samples (30 
mL) at the clinic. Using latex gloves, men collected se-
men specimens at home during masturbation within 24 
hours of each visit.  
For women, a cervical cytology (Papanicolaou [Pap]) 
smear was collected, and a swab and cytobrush were used 
to consecutively sample the ectocervix and endocervix, 
including the transformation zone. The same methods 
used for collection of anal, oral, hand, and urine speci-
mens from men were used for collection of specimens 
from women.
HPV DNA Testing and Genotyping
DNA was extracted from specimens by using com-
mercial reagents (QIAGEN, Valencia, CA, USA). The 
PCR used PGMY09/PGMY11 primers to amplify a 450-bp 
region of the L1 HPV genome (10). Ampliﬁ  cation of the 
human β-globin gene was included as an internal control 
for sample sufﬁ  ciency. HPV-positive specimens were sub-
sequently genotyped by using commercial reagents (Roche 
Molecular Systems Inc., Branchburg, NJ, USA) originating 
from a prototype line blot assay (11). The assay detects 37 
different HPV types, including oncogenic/probable onco-
genic types (HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 
56, 58, 59, 66, 68, 73, 82, and IS39, a subtype of HPV 82), 
nononcogenic types (HPV 6, 11, 40, 42, 54, 61, 70, 72, 81, 
and CP6108, also known as candidate HPV 89), and types 
with undetermined risk status (HPV 55, 62, 64, 67, 69, 71, 
83, and 84) (12,13). This PCR-based assay has demonstrat-
ed a high degree of sensitivity and reproducibility (14–16). 
HPV testing and genotyping procedures have been given in 
detail previously (9). 
Statistical Analysis
The main objective of the statistical analysis was to 
evaluate HPV transmission between partners. Each type-
speciﬁ  c HPV infection was assigned a status of transmitted 
or not transmitted by time period and anatomic site. For 
some statistics, the penis anatomic site was further divided 
into foreskin, glans, shaft, and urine, which is a proxy for 
urethral infection. HPV in female urine, which has dem-
onstrated type-speciﬁ  c concordance with cervical measure-
ments (17), was considered to be a proxy for cervical and 
other lower genital tract infections. Therefore, cervix and 
urine were combined as 1 anatomic site. When there were 
>1 possible source sites, sites were grouped and evaluated 
as 1 transmission event. When there were >2 destination 
sites, each was counted as a separate transmission event. 
Partner transmission was deﬁ  ned as the presence of 
a speciﬁ  c HPV genotype at an anatomic site in 1 partner 
and its absence in all sites of the other partner at a given 
visit, along with the presence of this HPV type in the un-
affected partner at the subsequent visit. Auto-inoculation 
was deﬁ  ned as the presence of a particular HPV type at an 
anatomic site in 1 partner and its absence in all sites of the 
other partner at a given visit, and the presence of this HPV 
type in a different anatomic site in the affected partner at 
the subsequent visit. An event was deﬁ  ned as self-inocula-
tion only after possible transmission from the partner was 
ruled out, i.e., when the partner was negative for the HPV 
genotype at prior and concurrent visits.
The rate of HPV transmission was calculated as the 
number of HPV type-speciﬁ  c transmission events divided 
by the number of person-months of exposure × 100 and 
expressed as the rate per 100 person-months. Exact conﬁ  -
dence intervals (CIs) for transmission rates were calculated 
by assuming a Poisson distribution for the number of events 
(18). Person-months of exposure for each HPV infection by 
anatomic site were computed based on the period of time be-
tween successive visits. When HPV was detected at a given 
visit and HPV type was absent at the successive visit, the 
exposure period was estimated at half of the visit interval. 
Comparisons between couples by transmission status were 
made by using the t test, χ2 statistic, and linear rank statistic.
Results
Study Participants 
Thirty-eight couples (38 men, 38 women) were en-
rolled. Six couples left the study, including 2 whose rela-
tionships ended. The present analysis focuses on 25 couples 
with at least 2 visits. Couples were followed up at ≈2-month 
intervals over an average of 7.5 months.  
The mean age was 28 years (range 18–59 years) for 
men and 26 years (range 18–57 years) for women. Partici-
pants comprised Caucasians (52%), Asians (8%), Paciﬁ  c 
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Islanders (6%), and persons of other single- or mixed-race 
backgrounds (34%). Couples were single/never married 
(48%), living together as married (32%), separated/di-
vorced/widowed (12%), and married (8%). All participants 
indicated that the index partner was their only current sex-
ual partner, and all reported vaginal intercourse with penile 
penetration during the follow-up period. 
Five men were uncircumcised. At study entry, 1 wom-
an had cervical low-grade squamous intraepithelial lesions, 
and 2 men had genital warts. Cervical atypia was diagnosed 
in 2 women during follow-up.
HPV Transmission
Overall, 957 (94%) of 1,015 specimens were adequate 
based on β-globin detection and were included in the pres-
ent analyses. At study entry, 7 couples were HPV negative 
at all anatomic sites, 4 couples had 1 HPV-positive partner 
(3 were anal infections in the man), and 14 couples had 
both partners HPV positive. Of the 14 couples positive for 
HPV, 3 couples were positive for different HPV types, and 
11 were positive for the same HPV type(s) at 1 or more ana-
tomic sites (Table 1). All 11 HPV type-speciﬁ  c concordant 
infections involved the penis in the male partner and, with 
2 exceptions, the cervix and/or urine in the female partner.
All transmission events occurred in couples with 1 or 
both partners positive for HPV at study entry. A total of 78 
transmission events were observed in 16 couples, including 
14 male-to-female, 39 female-to-male, 21 male auto-inocu-
lation, and 4 female self-inoculation (online Appendix Ta-
ble, available from www.cdc.gov/content/14/6/888-appT.
htm). Overall, 15 different genotypes were transmitted, in-
cluding oncogenic types and nononcogenic/undetermined 
risk types. Partner transmission involved 13 genotypes. 
Forty-one (53%) of the 78 transmission events involved 
multiple potential sources of infection.  
Male-to-female transmission was observed in 7 cou-
ples. All infections transmitted from male to female part-
ners originated in the penis with or without additional in-
volvement of the scrotum. In particular, the penis shaft was 
a predominant source of infection either alone or with other 
genital sites. The cervix and anus were the most frequent 
targets of transmission from the men. Transmission of on-
cogenic HPV 16 comprised 1 of the 5 genital-to-cervix 
events. Male genital to female hand transmission was ob-
served in 3 couples (D, E, and G). 
Female-to-male transmission was observed in 12 cou-
ples. Transmission from the cervix and/or urine to the male 
genitals comprised most female-to-male events. Within pe-
nis subsites, the glans was targeted more frequently than 
the shaft. The anus was frequently an additional source site 
along with the cervix/urine. In addition, the anus was the 
sole source of transmission to the male genitals on 4 occa-
sions, of which 3 targeted the partner’s scrotum (couples 
A, B, and J). The penis and scrotum, respectively, were the 
most frequent targets of infection from women. There were 
4 instances of transmission from the woman’s hands to the 
man’s genitals, including 1 case in which it was the sole 
source (couple I). Oncogenic HPV types 16 and 18 were 
transmitted in only 2 of the 39 female-to-male events.  
Male self-inoculation was observed in 11 men, includ-
ing 3 for whom no heterosexual transmission was observed 
during the entire period of follow-up. Sixteen events in-
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Table 1. HPV status of couples at study entry* 
Man Woman
HPV status at baseline  No. Site HPV Site HPV
Both partners HPV neg  7 All Neg All Neg
One partner HPV pos  4 Anus 18 All Neg
Anus 18 All Neg
Anus 42/51/52/84 All Neg
All Neg Urine CP6108
Both partners HPV pos 
  Different HPV type(s)    3 Anus 6 Anus 39
Shaft 6 Cervix/urine 16
Shaft, scrotum 6 Cervix/urine, anus 31
11 Shaft 59 Cervix 59    One or more of the  
  same HPV type(s)†   Shaft 59 Hand 59
Shaft 84 Cervix 84
Shaft 62 Urine 62
Shaft 55 Anus 55
Glans, shaft  56, 59  Cervix/urine, anus, hand  56, 59 
Shaft, scrotum  62 Urine, anus, hand  62
Foreskin, glans, shaft, scrotum CP6108 Urine, anus  CP6108
Shaft, scrotum 42 Cervix/urine, anus 42
Glans, shaft, scrotum  53 Cervix 53
*HPV, human papillomavirus; neg, negative; pos, positive.
†Only concordant types shown. Transmission of HPV in Couples
volved transmission between different genital sites, 2 in-
volved anal-to-genital transmission, and 3 involved geni-
tal-to-hand transmission. Most genital-to-genital events 
involved transmission between penis subsites. In 3 instanc-
es, male self-inoculation immediately preceded transmis-
sion of HPV to female partners (couples A and B).  
Female self-inoculation was observed in 4 females. 
All involved urine as a source site and 3 of these targeted 
the hands.
Heterosexual transmission of the same HPV genotype 
to >1 anatomic site (excluding penis subsites) was observed 
on 13 occasions. Eight of these cases involved transmission 
from the cervix/urine to the penis and scrotum.  
Heterosexual transmission of multiple genotypes to the 
same anatomic site during the same period was observed in 
5 instances (couples A, B, D, F, and G); the scrotum was 
the target site on 3 of these occasions. In 1 case, different 
genotypes in the cervix and urine were each transmitted to 
both the penis glans and shaft (couple K).   
Transmission of some HPV types in preference to oth-
ers was also observed. In couple L, after cervical infection 
with HPV 16 and 31 was detected at study entry, only HPV 
31 was transmitted to the penis (glans, shaft) and scrotum. 
Alternatively, the female anus may have been the source 
of infection because HPV 31, not HPV 16, was present in 
the anus at baseline. In couple D, HPV 16, 59, and 62 were 
present in the penis shaft at baseline. Subsequently, only 
HPV 16 was transmitted to the woman’s cervix/urine and 
anus by the second visit. 
A number of instances indicated apparent reinfection 
after viral clearance. In 1 couple (A), the woman’s anus 
was positive for HPV 39 infection at baseline and at visit 2. 
By visit 3, HPV 39 had been transmitted to the man’s scro-
tum, and the woman was negative for HPV 39. HPV 39 had 
been transmitted (presumably by auto-inoculation) to the 
penis by visit 4, and the infection remained through visit 5. 
By visit 6, or 9 months after initial clearance in the woman, 
HPV 39 had been transmitted to the woman’s anus.
Four cases of transmission to the female anus required 
>4 months of exposure to an infected partner. In 27 inci-
dent infections, no source of infection could be ascertained; 
17 of these infections were in the male genitals.  
The rates of HPV transmission by source site are 
shown in Table 2. Overall, the rate of transmission from the 
penis to the cervix/urine was 4.9 per 100 person-months of 
exposure (95% CI 1.6–10.0). By contrast, the overall rate 
of transmission from the cervix/urine to the penis was 17.4 
per 100 person-months of exposure (95% CI 10.6–25.8). 
Transmission of oncogenic types to the male genitals was 
greater from the female urine alone than from the cervix 
alone. Transmission of HPV from the penis to the female 
anus was higher than that to the cervix; this was particularly 
true for transmission of oncogenic types to the anus (12.2 
per 100 person-months of exposure, 95% CI 3.9–24.9). The 
highest rates of transmission were observed from the fe-
male anus to the male genitals (47.1 per 100 person-months 
of exposure, 95% CI 30.2–67.7), followed by cervix to the 
male genitals (27.8 per 100 person-months of exposure, 
95% CI 19.0–38.3). In men, the rate of transmission by 
auto-inoculation was comparable to that of transmission 
from women. For example, the rate of transmission from 
the scrotum alone to the penis (6.0 per 100 person-months 
of exposure, 95% CI 1.2–14.5) was comparable to that of 
cervix only to penis (5.0 per 100 person-months of expo-
sure, 95% CI 1.0–11.9).  
Behavioral Factors
All couples with genital-to-genital transmission re-
ported vaginal intercourse during the period corresponding 
to the transmission event. Among the 5 couples with penis-
to-anus transmission, 4 reported anal intercourse during the 
corresponding time period.  
Table 3 compares baseline characteristics of couples 
with and without HPV transmission. Male partners in trans-
mitting couples had had more sexual partners over their 
lifetime. Transmitting couples had more frequent sexual 
intercourse with one another, were more likely to have 
contact between the male’s mouth and the female’s anus, 
were more likely to use birth control injections and have 
withdrawal before ejaculation, and had fewer periods of 
abstinence. Over half of nontransmitting couples reported 
use of condoms 100% of the time during sexual intercourse 
within the previous 4 months, compared with only 3% of 
transmitting couples. 
Discussion
This study demonstrates that HPV is efﬁ  ciently trans-
mitted between sexual partners and that multiple transmis-
sion events can occur within a couple. The rates of genital 
transmission from women to men were substantially higher 
than from men to women. Greater rates of female-to-male 
transmission should imply higher HPV prevalence in men. 
Studies in men to date, including our own cohort, have re-
ported male genital HPV prevalences at least as high as in 
women, with most reporting prevalences of at least 20% 
and up to 73% (9,19). The penis shaft was the primary 
source of transmission to the cervix; the cervix and urine 
were the primary sources of infection to male genitals.  
Sexual transmission also involved the scrotum, the 
anus of women, and the hands of both sexes. The oral cav-
ity and semen were not involved in transmission. 
The anus of women was both a major source and tar-
get of heterosexual transmission. We observed consistency 
between penis-to-female anus transmission and reported 
anal intercourse during the corresponding period. We pre-
viously demonstrated high genotypic concordance between 
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concurrent cervical-anal infections in women, which indi-
cates possible common sources of infection (20). 
Transmission through nonpenetrative sexual contact 
was demonstrated between the female anus and the scro-
tum, as well as the female hand and male genitals. The male 
anus was not a major source or a target of HPV transmis-
sion. However, 3 of the 4 couples with baseline infection in 
only 1 partner involved anal infection in men.  
Male self-transmission frequently involved the scro-
tum, likely facilitated by passive contact between proxi-
mate genital sites. The scrotum may be an important 
reservoir of infection for penile infections that can subse-
quently be transmitted to partners. Hands may also serve 
as reservoirs of infection in both men and women. Auto-
inoculation involving the hands may result from casual 
contact or masturbation. 
To some extent, our study results suggest that HPV 
is relatively indiscriminate in its patterns of transmission. 
We observed the transmission of a given viral genotype to 
multiple anatomic sites in a partner and concurrent trans-
mission of multiple genotypes to the same site.
Other observations suggest that HPV transmission is 
not entirely arbitrary and may reﬂ  ect tissue or genotype dif-
ferences or both. Rates of transmission of oncogenic types 
to the male genitals from the urine were higher than from 
the cervix. This may reﬂ  ect differences in genotypes found 
in the vagina and vulva compared with those found in the 
cervix. All transmission events requiring extended periods 
of exposure involved the female anus target site.  
A total of 15 genotypes were transmitted, including 13 
which were transmitted through heterosexual means. HPV 
16 and 18 and nononcogenic HPV 6 and 11, the 4 types 
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Table 2. Rate of HPV transmission by source and target site in male-female couples* 
No. transmission 
events
Duration of exposure, 
mo†
Transmission rate/100 person-
months (95% CI) 
Source site  Target site  Overall Oncogenic Overall Oncogenic Overall Oncogenic‡
Male to female
  Penis only Cervix/urine 2 1 102 41 1.9 (0.2–5.4)  2.4 (0.06–9.0) 
 Penis  only Anus 3 3 102 41 2.9 (0.6–7.1)  7.3 (1.5–17.6) 
 Penis  only Hand 2 1 102 41 1.9 (0.2–5.4)  2.4 (0.06–9.0) 
  Any penis  Cervix/urine 5 1 102 41 4.9 (1.6–10.0)  2.4 (0.06–9.0) 
 Any  penis Anus 6 5 102 41 5.9 (2.2–11.4)  12.2 (3.9–24.9) 
 Any  penis Hand 3 2 102 41 2.9 (0.6–7.1)  4.9 (0.6–13.5) 
 Any  scrotum  Cervix/urine 3 0 50 – 6.0  (1.2–14.5)  –
 Any  scrotum Anus 3 2 50 27 6.0 (1.2–14.5)  7.5 (0.9–20.9) 
 Any  genital Cervix/urine 5 1 111 51 4.5 (1.5–9.3)  2.0 (0.1–7.2) 
 Any  genital  Anus 6 5 111 51 5.4 (2.0–10.6)  9.8 (3.2–20.0) 
Female to male
 Cervix  only  Penis 3 0 61 – 5.0  (1.0–11.9)  –
 Cervix  only Scrotum 1 0 61 – 1.6  (0.04–6.1)  –
 Cervix  only Any genital  4 0 61 – 6.6 (1.8–14.5)  –
 Urine  only Penis 2 1 55 36 3.7 (0.4–10.2)  2.8 (0.1–10.4) 
  Urine only Scrotum 3 2 55 36 3.7 (.04–10.2)  5.6 (0.7–15.7) 
 Urine  only Any genital  5 3 55 36 9.2 (3.0–18.8)  8.4 (1.7–20.3) 
 Cervix/urine  only Penis 6 2 115 83 5.2 (1.9–10.1)  2.4 (0.3–6.7) 
  Cervix/urine only Scrotum 5 3 115 83 4.3 (1.4–8.9)  3.6 (0.7–8.7) 
 Any  cervix/urine Penis 20 12 115 83 17.4 (10.6–25.8)  14.6 (7.5–23.9) 
 Any  cervix/urine  Scrotum 12 8 115 83 10.4 (5.4–17.1)  9.7 (4.2–17.4) 
 Any  cervix/urine Any genital  32 20 115 83 27.8 (19.0–38.3)  24.2 (14.8–35.9) 
  Any cervix/urine Anus 1 1 115 83 0.9 (0.02–3.2)  1.2 (0.03–4.50 
 Any  cervix/urine Hands 1 1 115 83 0.9 (0.02–3.2)  1.2 (0.03–4.5) 
 Anus  only Scrotum 3 1 51 36 5.9 (1.2–14.2)  2.7 (0.1–10.1) 
  Any anus Any genital  24 16 51 36 47.1 (30.2–67.7)  44.0 (25.1–68.0) 
 Any  hands Any genital  4 2 426 373 28.2 (7.7–61.8)  16.1 (1.9–44.8) 
Self-inoculation
 Male§ 
  Penis  only Scrotum 5 1 102 41 4.9 (1.6–10.0)  2.4 (0.1–9.0) 
    Scrotum only           Penis 3 2 50 27 6.0 (1.2–14.5)  7.5 (0.9–20.9) 
  Any  genital Any genital  15 6 111 51 13.6 (7.6–21.3)  11.7 (4.3–22.8) 
  Any  genital Hands 3 2 111 51 2.7 (0.6–6.5)  3.9 (0.5–10.9) 
    Anus only Any genital  3 2 29 21 10.2 (2.1–24.6)  9.3 (1.1–26.0) 
 Female 
  Cervix/urine  only Anus 1 1 115 83 0.9 (0.02–3.2)  1.2 (0.03–4.5) 
  Cervix/urine/anus Hand 3 2 166 119 1.8 (0.4–4.4)  1.7 (0.2–4.7) 
*HPV, human papillomavirus; CI, confidence interval. 
†Based on the duration of infection in the source site. When HPV was detected at a given visit followed by the absence of that HPV type at the 
successive visit, the exposure period was estimated at half of the visit interval.  
‡Includes probable oncogenic types. 
§Includes penis-to-penis subsite inoculations. Transmission of HPV in Couples
included in the current quadrivalent vaccine, comprised 
<10% of transmitted types. Notably, we observed greater 
transmission of HPV 16 to the cervix than such transmis-
sion by other types, which underscores the possibility of 
selective transmission of some HPV types.
Compared with couples not experiencing HPV trans-
mission, transmitting couples were more sexually active 
and were more likely to use certain nonbarrier forms of 
contraception. Few HPV-transmitting couples reported al-
ways using condoms during recent sexual activity, com-
pared with over half of nontransmitting couples. 
A major limitation of our study was the potential for 
misclassiﬁ  cation of HPV transmission events. Variable de-
tection of HPV could be due to natural ﬂ  uctuation in vi-
ral levels or variable sampling of sites could confound the 
observation of viral transmission. For example, instances 
of apparent reinfection of sites may alternatively represent 
possible reactivation of latent infections.
Another potential source of misclassiﬁ  cation was the 
lack of a priori knowledge of the time required for HPV 
to be acquired from an infected partner. Viral transmission 
could have occurred more frequently than the 2-month visit 
intervals used in the study, and transmission events could 
have been missed. 
Another limitation of the study was the inclusion of 
couples who had already had sexual contact with one an-
other; initial viral transmission was likely to have occurred 
before study entry. Indeed, nearly half of the couples had 
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Table 3. Characteristics of male-female couples by HPV transmission status* 
Characteristic Transmission (n = 16 couples) No transmission (n = 9 couples) p value 
Mean age (SD) 
  M  25.4 (8.8) 32.2 (14.4) 0.22
  F 25.5 (10.2) 26.3 (7.3) 0.82
Length of relationship, mo, median (range) 10.7 (1.9–73.4) 13.1 (0.23–185) 0.22
Monthly frequency of sexual intercourse, mean (SD)  17.7 (10.0) 6.9 (7.8) 0.0002
Lifetime no. sexual partners, mean (SD) 
  M  13.9 (10.4) 5.9 (5.1) 0.04
  F  6.7 (6.1) 2.8 (2.2) 0.08
Circumcised man, no. (%)  13 (81) 7 (78) 0.84
Sexual practices (ever/never), no. (%) 
  Vaginal intercourse 32 (100) 18 (100) 1.00
  Anal intercourse 14 (44) 6 (33) 0.47
  Oral-vaginal  29 (91) 13 (72) 0.09
  Oral-penile  32 (100) 17 (94) 0.18
  Oral (M)–anal (F)  6 (19) 0 0.05
  Oral (F)–anal (M)  2 (6) 0 0.28
  Finger/other object-vaginal 28 (88) 18 (100) 0.12
  Finger/other object (M)–anal (F) 9 (28) 4 (22) 0.65
  Finger/other object (F)–anal (M) 12 (38) 4 (22) 0.27
Contraception ever used with partner, no. (%) 
  Birth control pill 21 (66) 8 (44) 0.15
  Birth control shot 6 (19) 0 0.05
 “Morning  after”  pill 15  (16) 0 0.08
  Spermicides 3 (9) 2  (11) 0.84
  Withdrawal 19 (59) 5 (28) 0.03
  Vasectomy 2 (6) 4 (22) 0.10
  Female condom 2 (6) 3 (17) 0.24
  Abstinence 5 (16) 8 (44) 0.03
  Condom 26 (81) 16 (89) 0.48
Frequency of condom use (prior 4 mo), no. (%)  
  Always 1 (3) 10 (56)
 Never/some  use† 31 (97) 8 (44) <0.0001
Sexually transmitted infection history, no. (%) 
 Chlamydia  4  (13) 0 0.12
  Genital herpes  1 (3) 2 (11) 0.25
Cigarette smoking (ever)‡, no. (%)   
  M 9 (56) 3 (33) 0.27
 F4   ( 2 5 ) 0 0 . 1 0
*HPV, human papillomavirus; SD, standard deviation.                     . 
†Some use defined as usage less than half the time, half the time, or more than half the time. 
‡History of smoking daily for >6 months. RESEARCH
type-speciﬁ  c concordant infections at study entry, indicat-
ing previous transmission of HPV, which limited our abil-
ity to evaluate incident infections. 
Because our study relied on self-reported sexual ac-
tivity, it was subject to recall bias. Furthermore, although 
all persons reported monogamous relationships, some of 
the incident infections without a source, most of which in-
volved the male genitals, could have been acquired through 
sexual activity with another partner. Despite these limita-
tions, the present study included intensive follow-up of a 
well-characterized cohort, sampling of multiple genital and 
nongenital sites, and state-of-the-art HPV testing and geno-
typing methods.
The development of comprehensive HPV prevention 
and control strategies, which incorporate HPV vaccine 
usage and contraceptive practices, is impeded by lack of 
information on the risk and routes of sexual transmission 
between heterosexual partners and potential genotype-spe-
ciﬁ  c differences in transmission efﬁ  ciency. The small size 
of the cohort and the diversity of genotypes precluded type-
speciﬁ  c analysis of transmission.  
This study contributes to a growing body of knowledge 
of HPV in men because we directly examined HPV trans-
mission. However, study results are preliminary and need 
to be veriﬁ  ed in larger cohorts. Future HPV transmission 
studies are critical to address major gaps in our knowledge 
of the natural history of this virus.  
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